(Q39685538)

14 September 2017

title

Biomarkers Predicting Pathologic Complete Response to Neoadjuvant Chemotherapy in Breast Cancer (English)

1 reference

14 September 2017

0 references

1 reference

neoadjuvant chemotherapy

1 reference

6

Ruth O'Regan

1 reference

14 September 2017

Xiaoxian Bill Li

1

1 reference

14 September 2017

Uma Krishnamurti

2

1 reference

14 September 2017

Shristi Bhattarai

3

1 reference

14 September 2017

Sergey Klimov

4

1 reference

14 September 2017

Michelle D Reid

5

1 reference

14 September 2017

Ritu Aneja

7

1 reference

American Journal of Clinical Pathology

14 September 2017

language of work or name

English

1 reference

inferred from

publication date

12 June 2016

1 reference

American Journal of Clinical Pathology

14 September 2017

published in

1 reference

14 September 2017

volume

145

1 reference

14 September 2017

issue

6

1 reference

14 September 2017

page(s)

871-878

1 reference

Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer.

14 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQW045

Neoadjuvant therapy in the treatment of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQW045

Response-guided neoadjuvant chemotherapy for breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQW045

Neoadjuvant chemotherapy adaptation and serial MRI response monitoring in ER-positive HER2-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQW045

Selecting the neoadjuvant treatment by molecular subtype: how to maximize the benefit?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQW045

Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQW045

Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQW045

Delay in surgical treatment and survival after breast cancer diagnosis in young women by race/ethnicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQW045

Early prediction of pathologic response to neoadjuvant therapy in breast cancer: systematic review of the accuracy of MRI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQW045

Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATA

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQW045

Predictive biomarkers in breast cancer: their value in neoadjuvant chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQW045

Tumour molecular subtyping according to hormone receptors and HER2 status defines different pathological complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQW045

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQW045

Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQW045

Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQW045

Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQW045

GATA-3 and FOXA1 expression is useful to differentiate breast carcinoma from other carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQW045

Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQW045

Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQW045

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parall

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQW045

Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQW045

Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQW045

The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQW045

Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQW045

Neoadjuvant chemotherapy for "triple negative" breast cancer: a review of current practice and future outlook

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQW045

Predictors of complete pathological response after neoadjuvant systemic therapy for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQW045

Ki-67 as a predictor of response to neoadjuvant chemotherapy in breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQW045

Predictive Significance of p53, Ki-67, and Bcl-2 Expression for Pathologic Complete Response after Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQW045

Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQW045

Quantitative assessment Ki-67 score for prediction of response to neoadjuvant chemotherapy in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQW045

Pathological non-response to chemotherapy in a neoadjuvant setting of breast cancer: an inter-institutional study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQW045

The value of tumor infiltrating lymphocytes (TILs) for predicting response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQW045

Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQW045

Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer--a substudy of the neoadjuvant GeparQuinto trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQW045

21 January 2018

Identifiers

DOI

10.1093/AJCP/AQW045

1 reference

14 September 2017

1 reference